NO20005463L - Nye fettsyreanaloger for behandling av primær og sekundær restenose - Google Patents

Nye fettsyreanaloger for behandling av primær og sekundær restenose

Info

Publication number
NO20005463L
NO20005463L NO20005463A NO20005463A NO20005463L NO 20005463 L NO20005463 L NO 20005463L NO 20005463 A NO20005463 A NO 20005463A NO 20005463 A NO20005463 A NO 20005463A NO 20005463 L NO20005463 L NO 20005463L
Authority
NO
Norway
Prior art keywords
sub
treatment
fatty acid
primary
acid analogues
Prior art date
Application number
NO20005463A
Other languages
English (en)
Norwegian (no)
Other versions
NO20005463D0 (no
Inventor
Rolf Berge
Original Assignee
Thia Medica As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thia Medica As filed Critical Thia Medica As
Priority to NO20005463A priority Critical patent/NO20005463L/no
Publication of NO20005463D0 publication Critical patent/NO20005463D0/no
Publication of NO20005463L publication Critical patent/NO20005463L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Fats And Perfumes (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
NO20005463A 1998-05-08 2000-10-30 Nye fettsyreanaloger for behandling av primær og sekundær restenose NO20005463L (no)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NO20005463A NO20005463L (no) 1998-05-08 2000-10-30 Nye fettsyreanaloger for behandling av primær og sekundær restenose

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/NO1998/000143 WO1999058120A1 (en) 1998-05-08 1998-05-08 USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS
PCT/NO1999/000149 WO1999058123A2 (en) 1998-05-08 1999-05-07 Novel fatty acid analogues for the treatment of primary and secondary restenosis
NO20005463A NO20005463L (no) 1998-05-08 2000-10-30 Nye fettsyreanaloger for behandling av primær og sekundær restenose

Publications (2)

Publication Number Publication Date
NO20005463D0 NO20005463D0 (no) 2000-10-30
NO20005463L true NO20005463L (no) 2001-01-08

Family

ID=19907879

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20005463A NO20005463L (no) 1998-05-08 2000-10-30 Nye fettsyreanaloger for behandling av primær og sekundær restenose
NO20005462A NO333143B1 (no) 1998-05-08 2000-10-30 Nye fettsyreanaloger for behandling av diabetes
NO20005461A NO20005461L (no) 1998-05-08 2000-10-30 Nye fettsyreanaloger for behandling av obesitet, hypertensjon og fettlever

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO20005462A NO333143B1 (no) 1998-05-08 2000-10-30 Nye fettsyreanaloger for behandling av diabetes
NO20005461A NO20005461L (no) 1998-05-08 2000-10-30 Nye fettsyreanaloger for behandling av obesitet, hypertensjon og fettlever

Country Status (17)

Country Link
US (4) US6441036B1 (de)
EP (5) EP1285652B1 (de)
JP (3) JP5057003B2 (de)
KR (3) KR100701503B1 (de)
CN (3) CN1245157C (de)
AT (5) ATE245416T1 (de)
AU (4) AU7240398A (de)
BR (2) BR9910297A (de)
CA (3) CA2331395C (de)
DE (5) DE69932864D1 (de)
DK (3) DK1075258T3 (de)
ES (3) ES2204142T3 (de)
NO (3) NO20005463L (de)
NZ (3) NZ508045A (de)
PT (2) PT1075258E (de)
RU (3) RU2219920C2 (de)
WO (4) WO1999058120A1 (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2275140A2 (de) 2004-07-19 2011-01-19 Thia Medica AS Zusammensetzung enthaltend Pflanzen- oder Fischöl und nicht-oxidierbaren Fettsäuren-enthaltenden Komponenten
WO2014140934A2 (en) 2013-03-11 2014-09-18 Life Science Nutrition As Natural lipids containing non-oxidizable fatty acids

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7240398A (en) * 1998-05-08 1999-11-29 Rolf Berge Use of non-beta-oxidizable fatty acid analogues for treatment of syndrome-x conditions
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
AU784588B2 (en) * 1999-09-17 2006-05-04 Peplin Biolipids Pty Ltd Anti-inflammatory nitro- and thia- fatty acids
AUPQ291499A0 (en) * 1999-09-17 1999-10-07 Women's And Children's Hospital Adelaide Novel nitro and sulphur containing compounds
JP2003514855A (ja) * 1999-10-13 2003-04-22 チャコン，マルコ，エー． カロリー制限の効果を模倣した治療的介入
NO328803B1 (no) * 2000-03-03 2010-05-18 Thia Medica Nye fettsyreanaloger
NO20003591L (no) * 2000-07-13 2002-01-14 Thia Medica As Fettsyreanaloger for behandling av kreft
NO20004844L (no) * 2000-09-27 2002-05-10 Thia Medica As Fettsyre analoger for behandling av proliferative hudsykdommer
NO20006008L (no) * 2000-11-28 2002-05-29 Thia Medica As Fettsyreanaloger for behandling av inflammatoriske og autoimmune sykdommer
DE10115740A1 (de) * 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
IL142535A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
IL142536A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Carriers for therapeutic preparations for treatment of t-cell mediated diseases
ES2186576B1 (es) * 2001-10-11 2004-09-16 Universitat De Les Illes Balears Acido 2-hidroxioleico para utilizar como medicamento.
US6908632B1 (en) 2002-04-19 2005-06-21 Pharmanex, Llc Blood glucose modulating compositions and methods
DE60335810D1 (de) * 2002-05-28 2011-03-03 Ajinomoto Kk Medizinische zusammensetzungen zur hemmung der expression von atp-citrat-lyase und ihre verwendung
WO2004000854A1 (en) * 2002-06-20 2003-12-31 Ic Vec Limited Sulfur-containing phospholipid derivatives
US20080200453A1 (en) 2002-07-29 2008-08-21 Cincotta Anthony H Methods of treating metabolic syndrome using dopamine receptor agonists
US20040220190A1 (en) * 2002-07-29 2004-11-04 Cincotta Anthony H. Methods of treating metabolic syndrome using dopamine receptor agonists
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
US20040081678A1 (en) * 2002-08-09 2004-04-29 Anthony Cincotta Therapeutic process for the treatment of obesity and associated metabolic disorders
US7045547B2 (en) * 2002-08-20 2006-05-16 University Of Delaware Acyl-CoA dehydrogenase allenic inhibitors
MXPA05002575A (es) 2002-09-06 2005-09-08 Johnson & Johnson Compuestos heterociclicos.
CA2499983A1 (en) * 2002-09-27 2004-04-08 Martek Biosciences Corporation Docohexaenoic acid for improved glycemic control
CN100582085C (zh) * 2002-10-10 2010-01-20 耶达研究及发展有限公司 脂肪醇的碱性酯及它们作为抗炎药或免疫调节剂的用途
FR2850650B1 (fr) * 2003-01-31 2005-03-25 Genfit S A Utilisation therapeutique d'acylglycerols et de leurs analogues azotes et sulfures
FR2850869B1 (fr) * 2003-02-12 2005-03-25 Genfit S A Utilisations d'aminopropanediols acyles et de leurs analogues azotes et sulfures
EP1594439A2 (de) * 2003-02-13 2005-11-16 Albert Einstein College Of Medicine Of Yeshiva University Regulierung der nahrungsaufnahme und glukoseproduktion durch modulation der spiegel von langkettigem fettsäureacyl-coa im hypothalamus
JP2006520335A (ja) * 2003-03-18 2006-09-07 ノバルティス アクチエンゲゼルシャフト 脂肪酸とアミノ酸を含有する組成物
BRPI0507236A (pt) * 2004-01-30 2007-06-26 Peplin Biolipids Pty Ltd método para o tratamento ou profilaxia de uma condição, e, composto
US8137993B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US8137994B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US20050215558A1 (en) * 2004-03-25 2005-09-29 Cincotta Anthony H Methods of identifying responders to dopamine agonist therapy
AU2005250603A1 (en) * 2004-05-28 2005-12-15 Janssen Pharmaceutica N.V. New intravenous drug administration and blood sampling model in the awake rat
DE102004034640A1 (de) 2004-07-16 2006-02-16 Institut für Molekular- und Systemmedizin Verfahren zur systemischen Biokorrektur eines Organismus
RU2272628C1 (ru) * 2004-07-19 2006-03-27 Илья Николаевич Медведев Способ быстрой оптимизации функций кровяных пластинок при метаболическом синдроме
RU2394598C2 (ru) * 2004-07-19 2010-07-20 Тиа Медика Ас Композиция, содержащая белковый материал и соединения, содержащие неокисляющиеся структурные элементы жирных кислот
NO324534B1 (no) * 2004-07-19 2007-11-19 Thia Medica As Materiale fremstilt fra en kombinasjon av ikke-β-oksiderbare fettsyreanaloger og en planteolje eller fiskeolje samt anvendelser derav
WO2006041922A2 (en) * 2004-10-08 2006-04-20 Dara Biosciences, Inc. Agents and methods for administration to the central nervous system
US7288525B2 (en) * 2004-12-28 2007-10-30 The Research Foundation Of State University Of New York Method for lowering serum homocysteine
WO2006088875A2 (en) * 2005-02-14 2006-08-24 Albert Einstein College Of Medicine Of Yeshiva University Intranasal administration of modulators of hypothalamic atp-sensitive potassium channels
RU2441061C2 (ru) * 2005-05-04 2012-01-27 Пронова Биофарма Норге Эс. Производные докозагексаеновой кислоты и их применение в качестве лекарственных средств
WO2006117664A1 (en) * 2005-05-04 2006-11-09 Pronova Biopharma Norge As New dha derivatives and their use as medicaments
US7586003B2 (en) * 2005-07-14 2009-09-08 Zinpro Corporation Derivatives of seleno-amino acids
NO20053519L (no) * 2005-07-18 2007-01-19 Thia Medica As Anvendelse av forbindelser som omfatter fettsyrer
NO20055541L (no) * 2005-11-23 2007-05-24 Berge Biomed As Use of fatty acid analogues
GB0605900D0 (en) * 2006-03-23 2006-05-03 Lipigen As Modulators of nuclear receptors
US20080085293A1 (en) * 2006-08-22 2008-04-10 Jenchen Yang Drug eluting stent and therapeutic methods using c-Jun N-terminal kinase inhibitor
BRPI0718420A2 (pt) * 2006-10-20 2013-11-12 Cpd Llc Método de restabelecimento do efeito da incretina
CA2667211A1 (en) * 2006-11-01 2008-05-08 Pronova Biopharma Norge As Alpha-substituted omega-3 lipids that are activators or modulators of the peroxisome proliferators-activated receptor (ppar)
EP2129646A2 (de) * 2006-11-01 2009-12-09 Pronova Biopharma Norge AS Omega-3-lipidverbindungen
EP2117301A4 (de) * 2007-02-26 2010-04-14 Yeda Res & Dev Verwendung langkettiger alkoholderivate zur behandlung von kreisrundem haarausfall
US7964751B2 (en) * 2007-02-26 2011-06-21 Yeda Research And Development Co. Ltd. Enantiomers of amino-phenyl-acetic acid octadec-9-(Z) enyl ester, their salts and their uses
EP2214481B1 (de) 2007-10-15 2019-05-01 United Animal Health, Inc. Verfahren zur erhöhung der leistung von nachkommen
WO2009056983A1 (en) * 2007-10-31 2009-05-07 Pronova Biopharma Norge As New dha derivatives and their use as medicaments
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
MX2010011458A (es) * 2008-04-29 2010-11-09 Hoffmann La Roche 4-butiratos de trimetilamonio como inhibidores de la palmitoiltransferasa dependiente de carnitina 2 (cpt2).
EP2147910A1 (de) * 2008-07-15 2010-01-27 Pronova BioPharma Norge AS Neue Lipid-Verbindungen
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
AU2009293019A1 (en) 2008-09-19 2010-03-25 Tandem Diabetes Care Inc. Solute concentration measurement device and related methods
MY165292A (en) 2009-05-08 2018-03-21 Pronova Biopharma Norge As Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
EP2724739B1 (de) 2009-07-30 2015-07-01 Tandem Diabetes Care, Inc. Tragbares Infusionspumpensystem
US20130209550A1 (en) 2010-07-28 2013-08-15 Life Technologies Corporation Anti-Viral Azide Containing Compounds
US20120028335A1 (en) 2010-07-28 2012-02-02 Life Technologies Corporation Anti-viral azide-containing compounds
ES2618604T3 (es) 2010-11-05 2017-06-21 Pronova Biopharma Norge As Métodos de tratamiento usando compuestos lipídicos
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
CN105120842B (zh) 2013-02-28 2020-12-01 普罗诺瓦生物医药挪威公司 包含脂质化合物、甘油三酯和表面活性剂的组合物以及使用它们的方法
US10154979B2 (en) 2013-03-11 2018-12-18 Sciadonics, Inc. Lipid compositions containing bioactive fatty acids
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
RU2522224C1 (ru) * 2013-08-06 2014-07-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Уральская государственная академия ветеринарной медицины" Способ лечения острого гепатоза у кошек
ES2787223T3 (es) 2014-11-07 2020-10-15 Univ Minnesota Sales y composiciones útiles para tratar enfermedades
KR102644400B1 (ko) 2015-04-28 2024-03-06 바스프 에이에스 비알코올성 지방간염의 예방 및/또는 치료를 위한 구조적으로 강화된 함황 지방산의 용도
US10492141B2 (en) 2015-11-17 2019-11-26 Tandem Diabetes Care, Inc. Methods for reduction of battery usage in ambulatory infusion pumps
EP3661600A4 (de) * 2017-10-23 2021-08-11 Epitracker, Inc. Fettsäure-analoga und ihre verwendung zur behandlung von erkrankungen im zusammenhang mit dem stoffwechselsyndrom
HRP20241643T1 (hr) 2017-12-06 2025-02-14 Basf As Derivati masnih kiselina za liječenje nealkoholnog steatohepatitisa
AU2019274431B2 (en) 2018-05-23 2025-03-13 Epitracker, Inc. Compositions and methods for diagnosis and treatment of conditions related to the quality of aging and longevity
EP3908374A4 (de) 2019-01-09 2022-12-28 Epitracker, Inc. Zusammensetzungen und verfahren zur diagnose und behandlung von neurodegenerativen erkrankungen
WO2020180814A1 (en) 2019-03-04 2020-09-10 Epitracker, Inc. Fatty acid analogs and their use in the treatment of cognitive impairment, behavioral conditions, and chronic pain
EP4426130A1 (de) 2021-11-03 2024-09-11 Epitracker, Inc. Pentadecanoylcarnitin zur behandlung von alterungs- und langlebigkeitsbedingten leiden
KR20250043868A (ko) 2023-09-22 2025-03-31 건국대학교 산학협력단 옥시리핀을 유효성분으로 포함하는 비만 예방 또는 치료용 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59175425A (ja) * 1983-03-25 1984-10-04 Otsuka Pharmaceut Co Ltd 脳卒中予防剤
GB8813012D0 (en) * 1988-06-02 1988-07-06 Norsk Hydro As Non-b-oxidizable fatty acid analogues to reduce concentration of cholesterol & triglycerides in blood of mammals
US6063581A (en) * 1992-01-22 2000-05-16 Axis-Shield Asa Immunoassay for homocysteine
AU6277396A (en) * 1995-06-07 1996-12-30 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
NO952796D0 (no) * 1995-07-14 1995-07-14 Rolf Berge Fettsyre analoger med ikkeoksyderbart B-sete, fremstilling og anvendelse i krapeutiske preparater
PT843972E (pt) * 1996-11-20 2002-12-31 Nutricia Nv Composicao nutritiva que inclui gorduras para o tratamento do sindrome metabolico
AU7240398A (en) * 1998-05-08 1999-11-29 Rolf Berge Use of non-beta-oxidizable fatty acid analogues for treatment of syndrome-x conditions

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2275140A2 (de) 2004-07-19 2011-01-19 Thia Medica AS Zusammensetzung enthaltend Pflanzen- oder Fischöl und nicht-oxidierbaren Fettsäuren-enthaltenden Komponenten
WO2014140934A2 (en) 2013-03-11 2014-09-18 Life Science Nutrition As Natural lipids containing non-oxidizable fatty acids

Also Published As

Publication number Publication date
CA2331395A1 (en) 1999-11-18
HK1034911A1 (en) 2001-11-09
KR100822077B1 (ko) 2008-04-14
DE69910559D1 (de) 2003-09-25
CN1244323C (zh) 2006-03-08
NZ508047A (en) 2003-05-30
AU4936699A (en) 1999-11-29
EP1075259A1 (de) 2001-02-14
HK1034909A1 (en) 2001-11-09
ATE306916T1 (de) 2005-11-15
ATE334666T1 (de) 2006-08-15
KR100701502B1 (ko) 2007-04-02
BR9910297A (pt) 2002-01-02
ES2207253T3 (es) 2004-05-16
DE69910559T2 (de) 2004-06-17
ES2251218T3 (es) 2006-04-16
CA2331393A1 (en) 1999-11-18
AU4936799A (en) 1999-11-29
EP1075260A2 (de) 2001-02-14
DE69927805T2 (de) 2006-07-06
NO20005463D0 (no) 2000-10-30
JP2002514594A (ja) 2002-05-21
DE69909775D1 (de) 2003-08-28
EP1284139B1 (de) 2006-08-02
US7026356B2 (en) 2006-04-11
NO20005461L (no) 2001-01-08
AU762790B2 (en) 2003-07-03
KR20010043316A (ko) 2001-05-25
CA2331408C (en) 2008-10-21
EP1284139A1 (de) 2003-02-19
DE69909775T2 (de) 2004-06-03
CN1300211A (zh) 2001-06-20
ATE245416T1 (de) 2003-08-15
CN1302204A (zh) 2001-07-04
CA2331395C (en) 2008-10-14
EP1075258A1 (de) 2001-02-14
DK1075260T3 (da) 2006-02-06
RU2219920C2 (ru) 2003-12-27
CA2331393C (en) 2009-08-11
KR20010043314A (ko) 2001-05-25
AU7240398A (en) 1999-11-29
JP2002514595A (ja) 2002-05-21
US6441036B1 (en) 2002-08-27
AU761355B2 (en) 2003-06-05
DK1075258T3 (da) 2003-12-01
ATE336239T1 (de) 2006-09-15
PT1075258E (pt) 2004-01-30
NO20005462D0 (no) 2000-10-30
AU762792B2 (en) 2003-07-03
DE69927805D1 (de) 2006-03-02
ATE247464T1 (de) 2003-09-15
RU2221558C2 (ru) 2004-01-20
NO333143B1 (no) 2013-03-18
US6417232B1 (en) 2002-07-09
EP1285652A1 (de) 2003-02-26
KR100701503B1 (ko) 2007-04-02
CA2331408A1 (en) 1999-11-18
JP4465672B2 (ja) 2010-05-19
EP1075259B1 (de) 2003-07-23
US6365628B1 (en) 2002-04-02
US20020198259A1 (en) 2002-12-26
DE69932864D1 (de) 2006-09-28
NO20005461D0 (no) 2000-10-30
WO1999058123A3 (en) 2000-03-09
DK1075259T3 (da) 2003-11-03
CN1223343C (zh) 2005-10-19
WO1999058121A1 (en) 1999-11-18
WO1999058120A1 (en) 1999-11-18
EP1285652B1 (de) 2006-08-16
JP2002514596A (ja) 2002-05-21
NZ508046A (en) 2003-08-29
AU5451799A (en) 1999-11-29
JP5057003B2 (ja) 2012-10-24
EP1075260B1 (de) 2005-10-19
HK1034912A1 (en) 2001-11-09
KR20010043315A (ko) 2001-05-25
BR9910296A (pt) 2002-01-15
NZ508045A (en) 2003-08-29
WO1999058123A2 (en) 1999-11-18
NO20005462L (no) 2001-01-08
ES2204142T3 (es) 2004-04-16
PT1075259E (pt) 2003-12-31
CN1245157C (zh) 2006-03-15
DE69932645D1 (de) 2006-09-14
WO1999058122A1 (en) 1999-11-18
CN1300212A (zh) 2001-06-20
RU2223095C2 (ru) 2004-02-10
EP1075258B1 (de) 2003-08-20

Similar Documents

Publication Publication Date Title
NO20005463D0 (no) Nye fettsyreanaloger for behandling av primær og sekundær restenose
AU2019502A (en) Anilinopyrimidine derivatives as ikk inhibitors and compositions and methods related thereto
AU2721402A (en) Anilinopyrimidine derivatives as jnk pathway inhibitors and compositions and methods related thereto
DK1485359T3 (da) Natriumkanalblokkere
DE69928697D1 (de) Sulfohydroxamsäure and sulfohydroxamate und ihre verwendung als mek-inhibitoren
AP2002002637A0 (en) Novel piperazine
BR0113162A (pt) Ariloxialquilaminas nao-imidazóis
DE59902779D1 (de) Kristallmodifikation der liponsäure
TR200201128T2 (tr) PDE4 inhibitörleri olarak tetrahidrotiyopiranfitalazinon türevleri.
BR0212899A (pt) Compostos orgânicos
BR0012751A (pt) Benzofuranos serotonérgicos
IL166164A0 (en) 6-amino-1h-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors
TR199903159T2 (xx) Yeni �-Amino ve �-Azido karbonik asit t�revleri.
SI1651596T1 (sl) Novi derivati ditiobis aminobutan sulfonatov in sestavki ki jih vsebujejo
DE69405760D1 (de) 4-aza-pregnan-5-alpha-reductase isozym 1 inhibitoren
EP1195377A4 (de) Diester der malein- und fumarsäure
NO20026246D0 (no) 2-aminoalkyl-tieno[2,3-d]pyrimidiner
WO2004020417A8 (en) 2,4-diaminoquinazoline, 2-amino-4-hydroxypteridine and 2,4-diaminopyrimidine ester derivatives as dihydrofolate reductase inhibitors
BR0316971A (pt) Fenilalquinas
MX9708155A (es) Inhibicion de la fotodescomposicion de 2-oxindoles 3-sustituidos.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application